Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
|
|
- Griffin Wade
- 5 years ago
- Views:
Transcription
1 Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
2 5-year prostate cancer specific survival rates have improved from 67% to 99% between 1974 and 2000 Excellent survival data do not reflect the real problems for patients at risk for morbidity and mortality due to advanced or advancing disease
3 PSA/M1/CaP Deaths Baylor Washington University Mayo Clinic Johns Hopkins Number of Men 1,000 3,478 3,170 2,404 Metastases (10 yrs) 16% N/A 18% 10% Dead due to CaP (10 yrs) 2% 3% 10% 6%
4 Anatomical A, B, C, D T 1,2,3,4 N+, M+ Biological Grade, PSA (kinetics - Pre / Post) Hormonal Status Androgen dependant Androgen independent Castrate Independent Hormone refractory
5 First-Line Hormone Therapy, Prostate Cancer, United States, 2008 Hormone Therapy % of Patients LHRH analog only, continuous 38.2 CAB, continuous 25.5 LHRH analog, intermittent 17.3 CAB, intermittent 9.2 Orchiectomy only 5.0 Antiandrogen only alpha-reductase inhibitor only 1.4 Diethylstilbestrol only 0.8 Abbreviation: CAB=complete androgen blockade. Source: Survey of 128 physicians who treat a total of 10,741 prostate cancer patients monthly, conducted in August 2008; Mattson Jack DaVinci, The Mattson Jack Group, Inc.
6 6500 men in 20 trials of CAB vs monotherapy nilutamide or flutamide CAB better by 2.9% at 5 years 27.6% vs 24.7% (SE 1.3) Log rank 2p=0.05 Lancet 2000,355:1496
7 Japanese men with untreated advanced CaP: Stage C/D (T 3, N+, M+) Significant OS advantage in favor of CAB with bicalutamide 80mg vs LHRH-A monotherapy 5-year OS estimated by the Kaplan-Meier method was 75.3% for CAB vs 63,4% for LHRH-A monotherapy log-rank test: P= CANCER 2009,115:3437
8 For M+ CaP, ADT is superior to therapy for any other adult epithelial cancer >50% M+ still alive at 24 months (median) BUT IT CAN BE BETTER!
9 Surgery / Radiation Under the Care of UROLOGIST Under the Care of ONCOLOGIST Traditional Hormonal Therapy Antiandrogen Androgen Deprivation (CAB) Others Transdermal Estradiol Ketoconizole MDV-3100 Abiraterone Chemotherapy Local Therapy Therapies After LHRH Agonists and Antiandrogens Death Postchemotherapy PROVENGE TAXOTERE JEVTANA ZIBOTENTAN 9
10 Controversy whether there is a relationship between ADT and cardiovascular events and mortality [CA Cancer J Clin.60(3): , 2010] Patients receiving ADT need to also receive appropriate secondary preventive measures: Lipid lowering therapy Antihypertensive therapy Glucose-lowering therapy Anti-platelet therapy
11 60 yr old 5 years post RP pt3a, Gleason st PSA Rise - Two yrs PO Salvage EBRT + 6 mos A.D. 2 nd PSA Rise CAB X 2 yrs 3 rd PSA Rise continues after AAW Age 65 - PSA 3.0 What is Disease State?
12 Rising PSA after A.D. Hormone refractory - No Androgen independent - No Castrate resistant - Maybe If to med / surg cast - Yes and T<50/20 ng/dl If to all serum and -?? / No tissue T
13 < 50 ng/dl Traditional FDA cut point (assay limitation/lhrha approval) <20 ng/dl - Orchiectomy cut point/ more senstive assay <1 or 0.1 ng/dl Ultrasensitive assay Furthermore, serum T tissue T
14 Historically Testosterone = Serum T by conventional assay (endocrine) Today and Future Serum T by ultra-sensative assay Tissue T (paracrine)
15 Androgen levels in CaP tissue are sufficient to drive the androgen receptor even in a castrate state Benign Prostate (n=32;gray) Castration-Recurrent CaP (n=23;white) Mohler J et al, Clin Cancer Res, 2004;10(2):440-8
16 Not only is androgen present in the tissue, but enzymes needed to generate androgens are there it is self-sustaining Montgomery R et al. Cancer Res 2008;68(11):
17 Patients (%) < 20 ng/dl ng/dl > 50 ng/dl Testosterone (ng/dl) Morote et al. J Urol 2007;178:
18 P =.0207 AIPC Survival (mo) < 20 ng/dl ng/dl > 50 ng/dl 20 0 Testosterone (ng/dl) Morote et al. J Urol 2007;178:
19 Breakthrough increases of serum T are not only frequent but also have clinical implications for PSA progression There is a direct relationship between T increases (even in range) and PSA progression
20 162 M1 pts monitored with q3mos PSA + T at LHRH-A inj T at 6 months correlates with survival; p<0.05 and remains so on MV analysis EXAMPLE: patient with Gleason Score =7, PSA 50, at 6 months If T = 10ng/ml 60% 5-year survival If T = 40 ng/ml 54% 5-year survival BJU Int 2009;105:648 J Urol 2008; 179 (suppl)
21 Response should be monitored by measuring serum levels of testosterone
22 Amplification - Quantitative Hypersensitivity - Qualitative Mutation - Alternative Promiscuity - Available LIAR Ligand Independent (Cytokines, protein kinasis)
23 Even a small amount of androgen can fuel tumor proliferation AR increase captures any small amount of androgen available Increase coactivators and corepressors, which sensitize the ARs to androgen and nonandrogen ligands Androgen to undetectable levels is critical to control of advanced prostate cancer Question Initial or Subsequent Strategy?
24 Concept authentic Agents suboptimal against Ligand T Receptor Re-evaluation / Re-application (new agents) Serum Tissue T, DHT, DHEA, Epi A
25 Adrenal and tissue androgen synthesis inhibitors Ketoconazole, abiraterone acetate AR inhibitors: MDV3100 Estrogen: Estradiol transdermal patch 5-ARI: finasteride, dutasteride Alternate current anti-androgens GnRH antagonists: degarelix
26 Absorbed best in acidic milieu Dose q. 8 hrs Individualize dose Maximally tolerated dose can range from 100 to 800 mg every 8 hours. Start at mgs & slowly increase if necessary
27 Drugs made more active by Ketoconazole Statins Erythromycin & related (Z-pack) Calcium channel blockers (Norvasc, Procardia) Alprazolam (Xanax) SSRIs (Zoloft, Celexa, Lexapro, Prozac) Pain relief - acetaminophen (Tylenol)
28 Ketoconazole combined with hydrocortisone and dutasteride in asymptomatic castration-resistant CaP Response proportion to combination was at least comparable to prior studies of ketoconazole alone Time-to-progression for combination was substantially longer Combination warrants further investigation Clin Cancer Res 2009;15 (22):
29 Maximal change in PSA from baseline among 57 CRPC pts treated with KHAD >50% PSA decline = 56% >90% PSA decline = 28% 30% objective response Median response 20 months Clin Cancer Res 2009;15 (22):
30 Orally administered C17,20 lyase, 17 α-hydroxylase inhibitor Inhibits 3 sources of androgen production: testis, adrenals and tumor 10x more powerful Irreversible
31 Androgens produced at 3 critical sites lead to tumor growth Testes Adrenal glands Prostate tumor cells Abiraterone inhibits biosynthesis of androgens that stimulate tumor cell growth 1-5 Sources: 1. Attard et al. J Clin Oncol Attard et al. J Clin Oncol. 2009; 3. Reid et al. J Clin Oncol. 2010; 4. Ryan et al. J Clin Oncol. 2009; 5. Danila et al. J Clin Oncol
32 OH O O O HO P450 SCC Aldosterone HO Cholesterol HO O O Pregnenolone Progesterone Corticosterone P450 17α 21-hydroxylase (17α-hydroxylase) 11β-hydroxylase OH O O O OH OH HO OH HO O O 17α-Hydroxypregnenolone 17α-Hydroxyprogesterone Cortisol P450 17α (C 17,20 -lyase) O O testosterone 5α-reductase OH OH HO O O O H Dehydroepiandrosterone Androstenedione Testosterone 5α-Dihydrotestosterone
33 OH O O O HO P450 SCC Aldosterone HO Cholesterol HO O O Pregnenolone Progesterone Corticosterone P450 17α 21-hydroxylase (17α-hydroxylase) 11β-hydroxylase OH O O O OH OH HO OH HO O O 17α-Hydroxypregnenolone 17α-Hydroxyprogesterone Cortisol P450 17α (C 17,20 -lyase) O O testosterone 5α-reductase OH OH HO O O O H Dehydroepiandrosterone Androstenedione Testosterone 5α-Dihydrotestosterone Corticosterone is an active glucocorticoid
34 O O O HO OH P450 SCC Aldosterone HO Cholesterol HO O O Pregnenolone Progesterone Corticosterone P450 17α 21-hydroxylase (17α-hydroxylase) 11β-hydroxylase OH O O O OH OH HO OH HO O O 17α-Hydroxypregnenolone 17α-Hydroxyprogesterone Cortisol P450 17α (C 17,20 -lyase) O O testosterone 5α-reductase OH Synthesi s Increase d By ACTH OH HO O O O H Dehydroepiandrosterone Androstenedione Testosterone 5α-Dihydrotestosterone
35 96 patients with CRPC 88 M+ chemo-naïve Dose 1000 mg PSA decline > 50% decline: 67% pts > 90% decline: 19% pts Objective response: 37% CTC > 5 to < 5 = 59% JCO 27, 2009
36 Attard et al. J Clin Oncol Prechemotherapy Ryan et al. ASCO % PSA Decline 90.0% 50% PSA Decline 87.9% 90% PSA Decline 48.5% Danila et al. J Clin Oncol Postchemotherapy 30% PSA Decline 68.1% 50% PSA Decline 51.1% 90% PSA Decline 14.9% Reid et al. J Clin Oncol
37 CRPC M1 Randomization 2:1 Abiraterone 1000 mg daily Prednisone 10 mg daily Placebo daily Prednisone 10 mg daily Overall Survival 25% Completed Results 2010
38 Abiraterone (n=797) Placebo (n=398) Total (n=1195) Median age, years (range) 69.0 (42-95) 69.0 (39-90) 69.0 (39-95) Race, % White Black Asian ECOG PS 2, % Significant pain present, % Prior chemotherapies, %
39 Primary site of disease, % Abiraterone (n=797) Placebo (n=398) Bone Node Liver Lung
40 HR=0.646 ( ) P < Abiraterone: 14.8 months (95% CI: 14.1, 15.4) Overall Survival, % Placebo: 10.9 months (95% CI: 10.2, 12.0) 1 Prior Chemo OS: 15.4 months abiraterone vs 11.5 months placebo Days from Randomization Abiraterone Placebo
41 Abiraterone (n=791) Placebo (n=394) AE, % All Grades Grades 3/4 All Grades Grades 3/4 Fluid retention Hypokalemia LFT abnormalities Hypertension Cardiac disorders
42 CRPC Non-Metastatic 1:1 Abiraterone 1000 mg daily Prednisone 10 mg daily Placebo daily Prednisone 10 mg daily Progression Free & Survival 25%
43 Blocks androgen receptor with greater affinity than bicalutamide Impairs nuclear translocation and DNA binding of the androgen receptor Disables co-activators
44 114 pts with CRPC M+ >50% fall in PSA 37/65 (57%) CTx naïve 24/49 (50%) CTx CTC 21/43 ( 50%) unfavorable to favorable Well tolerated dose 160 mg for Phase III Phase III trial to open ASCO GU-2009; Abst 151, 5011
45 MDV 3100 (160 mg) CRPC M1 Randomized 2:1 Survival 25% Pcb or Prednisone
46 We suggest that the equivalence of the 1.0 and 5.0 mg doses plus the apparent superiority of 5.0 mg DES over orchiectomy alone in retarding cancer growth indicated that DES acts directly on the cancer cells in addition to inhibiting testosterone secretion. Byer NCI Mongr 1998;7:
47 BJU 1991; 67:84
48 VAURG Trial: Oral estrogens: (DES) cancer specific survival but lower overall survival, due to CV & TE events LHRH A: avoids CV & TE events of oral estrogens but causes bone, lipid, cognitive changes Estrogen transdermal delivery can reduce/ avoid CV, TE and bone/cognitive side effects Win:Win - Better efficacy, reduced AE and better QOL
49 T No aromatization E Erectile dysfunction Osteoporosis Sarcopenia Lipid changes Weight gain Hot flashes Diabetes Cognitive dysfunction
50 T No aromatization E Erectile dysfunction Osteoporosis Sarcopenia Lipid changes Weight gain Hot flashes Diabetes Cognitive dysfunction
51 Estradiol suppresses tissue androgens and CaP growth in castration resistant disease Estrogen suppresses tumoral androgens despite castrate T levels BMC Cancer 2010; 10: 244
52 Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer Control Arm 2200 Randomization Investigational Arm LHRH analogues given as per local practice indefinitely Transcutaneous estrogen patches indefinitely Primary endpoint: Overall Survival Secondary Endpoint: Castrate T, PSA failure, Toxicity, QOL, Prostate Specific Mortality
53
54
55 Percent Survival Placebo (n = 171) Median Survival: 21.7 Mos. P = (Cox model) HR = [95% CI: 0.614, 0.979] Median Survival Benefit = 4.1 Mos. Sipuleucel-T (n = 341) Median Survival: 25.8 Mos Survival (Months) Kantoff P, et al. NEJM 2010; 363:411
56 Trial / Agent Approved Disease State Comparator Hazard Ratio Difference in OS, months P Value IMPACT 1 (Provenge) 2010 TAX327 2 (Taxotere) 2004 TROPIC 3 (Jevtana) 2010 COU-AA-301 (Abiraterone acetate) 2010 Chemo-naive CRPC Chemo-naive CRPC Postdocetaxel CRPC Postdocetaxel CRPC Placebo Mitoxantrone Prednisone Mitoxantrone Prednisone Placebo Prednisone Sources: 1. Kantoff et al. N Engl J Med. 2010;363: ; 2. Tannock et al. N Engl J Med. 2004;351: ; 3. debono et al. Lancet. 2010;376: < <0.0001
57 Non-met Or met Rising PSA Met-CRPC Rising PSA Met-CRPC clinical / Symptomatic Met-CRPC Post-Chemo Chemotherapy Urology Medical Oncology
58 Non-met Or met Rising PSA Met-CRPC Rising PSA Met-CRPC clinical / Symptomatic Met-CRPC Post-Chemo Abiraterone MDV 3100 Sipuleucel T Chemo Abiraterone MDV 3100 Sipuleucel T Urology and Medical Oncology
59 Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
60 A 68-year-old male with T2b Gleason 4+4 cancer has opted for external beam radiation and three years of androgen deprivation. Past history reveals placement of cardiac stents at age 65, well controlled hypertension and diabetes, a vertebral compression fracture two years ago, and a 30 year pack history.
61 True / False While on AD, the patient is at risk for: Worsening hypertension Uncontrolled diabetes Osteoporosis
62 In addition to discussing decreased libido, energy, and prevalence of hot flashes, his urologist should: a. Communicate with primary care regarding BP, glucose, lipid, and anti-platelet therapy b. Schedule bone mineral density and plan antireabsorptive therapy c. Obtain 25 OH vitamin D level and begin vitamin D3 and calcium supplement d. Counsel patient regarding regular exercise and smoking cessation e. All the above
63 Oliver Sartor, M.D. LaBorde Professor of Cancer Research Depts. of Medicine and Urology Tulane Medical School New Orleans, LA
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationMapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD
Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD The University of Athens Medical School Dept of Clinical Therapeutics Prostate Cancer Evolution Chemotherapy
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationmajority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationWhat s New in Advanced Disease (CRPC)?
What s New in Advanced Disease (castration resistant prostate cancer = CRC)? Matthew Rettig, MD Associate rofessor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director,
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationAnti-Androgen Therapies for Prostate Cancer: A Focused Review
Anti-Androgen Therapies for Prostate Cancer: A Focused Review Nischala Ammannagari, MD, and Saby George, MD, FACP Abstract Among men in the United States, prostate cancer is the most common malignancy
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationMaximal androgen blockade versus castration alone in patients with metastatic prostate cancer*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0037-9 September 2014, Vol. 13, No. 9, P417 P421 Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer* Abeer
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationSAMPLE ONLY. Your Health Matters. Advanced Prostate Cancer and its Treatment A Patient Guide. Please order from Documents and Media: 415/
Your Health Matters Advanced Prostate Cancer and its Treatment A Patient Guide UCSF Genitourinary Medical Oncology Program Charles Ryan, MD, UCSF Patient Advocates Please order from Documents and Media:
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationLUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationAndrogen deprivation therapy: New concepts. Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto
Androgen deprivation therapy: New concepts Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto Clinical Research funding: 1. Bayer/Algeta 2. Ferring 3. Abbott 4. GSK 5. EMD Serono
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationCME Baseline Curriculum Report
CME Baseline Curriculum Report October 14, 2010 For CME Activity: Managing Advanced Prostate Cancer in the Community Setting: A Case-based Curriculum Supported by an independent educational grant from
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationTwo late stage clinical programs
Safe harbor This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject
More informationProstate Cancer: Vision of the Future By: H.R.Jalalian
1 H. R. Jalalian Hematologist&Oncologist Baqiyatallah University of Medical Sciences 2 State of the art: vision on the future Diagnosis Surgery Radiotherapy Medical Oncology 3 Early Detection PSA sensitivity
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationEvolution of Chemotherapy for. Cancer
Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationEdward P. Gelmann, MD
Prostate Cancer Edward P. Gelmann, MD Prostate Cancer Etiology and Ep pidemiology Screening Pathology Staging Localized Disease Metastatic Disease normal prostate epithelium GSTP1 CpG island hypermethylation
More informationLecture 10: Hormonal agents
Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More information